Trial Profile
A study evaluating patency of everolimus-eluting bioresorbable scaffolds at one year.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Sep 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery restenosis
- Focus Therapeutic Use
- 27 Sep 2017 New trial record
- 30 Aug 2017 Results (n=33) of preliminary analysis presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology